Drug Discovery Today

OCTOBER 28, 2021

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.

113

113

Drug Patent Watch

OCTOBER 23, 2021

This chart shows the patent expirations for ointment dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Ointment dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 84

Drugs 84

Drug Channels

OCTOBER 25, 2021

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. This chart complements Follow the Dollar: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. To further help you understand this channel, I have also included a brief video to explain the buy-and-bill system.

Pharmacy 74

Pharmacy Drugs Pharmaceuticals Hospitals 74

The Pharma Data

OCTOBER 29, 2021

– Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye’s ability to focus on near objects, affecting most adults over the age 40 – Phase 3 clinical studies demonstrated VUITY works in as early as 15 minutes and lasts for up to 6 hours, as measured on day 30, to improve near and intermediate vision without impacting distance vision – Allergan, an AbbVie company, continues legacy of eye care innovation with VUITY, a first-of

FDA Approval 52

FDA Approval FDA Treatment Drugs 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Discovery Today

OCTOBER 28, 2021

Highly consistent and scalable supply of lab grown human skeletal muscle cells provide an effective and biologically relevant tool for research and drug development in conditions as diverse as metabolic and muscle diseases and ageing.

Research 100

Research Drug Development Drugs Disease 100

Drug Patent Watch

OCTOBER 29, 2021

This chart shows the drugs with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 75

Pharmaceuticals Drugs 75

The Pharma Data

OCTOBER 29, 2021

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments 1 In the pivotal Phase III ASCEMBL trial, Scemblix demonstrated significant and clinically meaningful superiority in major molecular response (MMR) rate vs.

FDA Approval 52

FDA Approval Treatment FDA Trials 52

Crown Bioscience

OCTOBER 27, 2021

In this post we explore how using a range of translational preclinical models can be used to accelerate the discovery and validation of predictive biomarkers, with the goal of de-risking drug development to increase the likelihood of clinical success for therapeutic candidates.

Drug Development 52

Drug Development Drugs 52

Drug Patent Watch

OCTOBER 26, 2021

This chart shows the drugs with the most patents in Chile. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Chile? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 59

Pharmaceuticals Drugs 59

Practical Cheminformatics

OCTOBER 24, 2021

One of the most common tasks in Cheminformatics is exploratory data analysis (EDA). Given a new dataset, we often need to rapidly explore the chemistry in a set containing hundreds, or even thousands, of molecules. One useful technique for EDA is the Bemis-Murcko framework. This technique, originally published by Guy Bemis and Mark Murcko, provides a simple but elegant means of grouping molecules.

52

52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

The Pharma Data

OCTOBER 28, 2021

Lower talk, further action New report patronized by ViiV Healthcare provides roadmap to achieve health equity by 2040. ViiV Healthcare blazoned the release of Achieving health equity a roadmap to barring difference, a new report conducted by Economist Impact, a division of The Economist Group, that explores the openings that could be created by barring health difference in the UK and US over the coming 20 times, while charting a bold course for unified action.

International 52

International Drugs Research 52

Drug Channels

OCTOBER 27, 2021

Fortunately, Halloween can’t be scarier than any other day this year. So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! Brrr.did you hear that? It’s the biosimilar boom! Creepy! Scream as Blue Cross Blue Shield frightfully overpays hospitals Shocking!

Biosimilars 75

Biosimilars Hospitals Independent Pharmacies Pharmacy 75

Drug Patent Watch

OCTOBER 29, 2021

Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are…. The post New patent expiration for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

PerkinElmer

OCTOBER 26, 2021

Since the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a global pandemic on March 11, 2020, researchers around the world have been working tirelessly to discover effective preventive treatments and therapeutic agents. Currently, the FDA has only approved one drug, Veklury (remdesivir), for treatment of COVID-19.

Virus 52

Virus RNA Research Treatment 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

The Pharma Data

OCTOBER 28, 2021

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be enforced successfully in a variety of European healthcare settings. ViiV Healthcare, the global specialist HIV company maturity possessed by GlaxoSmithKline plc (“ GSK”), with PfizerInc. and Shionogi Limited as shareholders, moment presented positive interim data from the CARISEL (Cabotegravir and Rilpivirine Perpetration Study in European Locales) study, which was initiated and condu

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment RNA Pharmaceuticals 52

Eye on FDA

OCTOBER 28, 2021

Recently it was reported that the President Biden appears ready to nominate former FDA Commissioner Robert Califf to boomerang back and head the agency for a second time. If so, he returns to very different circumstances than when he left FDA in January 2017 after an 11-month stay. While FDA is accustomed to controversy while making difficult decisions, lately, it is much more than that.

FDA 79

FDA Science Vaccine Treatment 79

Drug Patent Watch

OCTOBER 28, 2021

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

The Pharma Data

OCTOBER 28, 2021

New analysis from the Phase III FIGARO-DKD study will be presented, which investigated the impact of finerenone on renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) / A subgroup analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will be presented, which investigated the impact of finerenone on renal outcomes on top of standard of care / Additional finerenone data from the FIDELIO-DKD study and the pooled analysis FIDELITY wi

Clinical Trials 52

Clinical Trials Trials Disease Hospitals 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

The Pharma Data

OCTOBER 28, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below. “At our current share price, we see an opportunity to buy back our shares at a substantial discount to what we perceive is their underlying value,” said Costa Saroukos, directo

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Therapies Engineering 52

The Pharma Data

OCTOBER 28, 2021

Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER ( 1). Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent ® , Vaccines and CHC. Specialty Care deals increased20.2 with strong donation from Dupixent ® (54.6 to€ million).Vaccines up16.5, with record daily deals driven by discerned flu vaccines and meningitis ballot recovery.

Vaccine 52

Vaccine Treatment Drugs 52

Drug Patent Watch

OCTOBER 27, 2021

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Romania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Romania? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

OCTOBER 27, 2021

Annual Drug Patent Expirations for ERLEADA Erleada is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are nine patents…. The post New patent for Janssen Biotech drug ERLEADA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

OCTOBER 27, 2021

GSK Consumer Healthcare today unveils a three-year programme to support the pharmacy profession with additional practical resources, mental health provisions and proposed policy changes as part of its new report Standing with Pharmacists in the Age of Self-Care. The new report summarises findings from a roundtable hosted by GSK Consumer Healthcare in collaboration with the International Pharmaceutical Federation (FIP) earlier this year, which convened the pharmacy community, policy experts, and

Pharmacy 52

Pharmacy International Pharmaceuticals Regulations 52

The Pharma Data

OCTOBER 27, 2021

Filings supported by pivotal ELARA trial, where treatment with Kymriah showed robust response rates and remarkable safety profile in adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) 1 Kymriah also received orphan drug designation from the European Commission (EC) for patients with FL earlier this year Patients with FL who are refractory to treatment or relapse after two prior lines are in need of durable alternatives to traditional therapies as the efficacy of treatments

FDA 52

FDA Treatment Trials FDA Approval 52

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

OCTOBER 27, 2021

FIRST-EVER GENERIC COMPANY SUSTAINABILITY-LINKED NOTES. Company will Increase Access to Medicines in Middle and Low Income Countries. Enhanced Commitment to the Environment. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $4,000,000,000 of sustainability-linked senior notes. The notes offering reflects Teva’s strong environmental, social and governance (ESG) commitment to some of the greatest challenges of our time by setting novel ambiti

Pharmaceuticals 52

Pharmaceuticals Government Production Marketing 52

The Pharma Data

OCTOBER 27, 2021

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat COVID-19. Tests conducted in hamsters improved the animal clinical conditions. The neutralizing activity of the sera developed by the scientists has been proved to be high against the P.1 (Gamma) and P.2 variants.

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

Drug Patent Watch

OCTOBER 26, 2021

Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are seventeen…. The post New patent for Vanda Pharms drug HETLIOZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 26, 2021

Annual Drug Patent Expirations for IMCIVREE Imcivree is a drug marketed by Rhythm and is included in one NDA. There are two patents protecting this drug. This drug has forty-three…. The post New patent for Rhythm drug IMCIVREE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 26, 2021

Annual Drug Patent Expirations for TRULANCE Trulance is a drug marketed by Salix and is included in one NDA. It is available from two suppliers. There are eight patents protecting…. The post New patent for SALIX drug TRULANCE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 26, 2021

Annual Drug Patent Expirations for HETLIOZ+LQ Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Vanda Pharms drug HETLIOZ LQ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

OCTOBER 25, 2021

CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) 1 Potentially clinically meaningful improvements in both PFS and OS were observed among pre-specified subgroups of patients with inflammatory biomarkers; additional analyses are ongoing 1 Results support continued study of canakinumab in earlier stages of lung cancer, as pot

Clinical Trials 52

Clinical Trials Trials Treatment Drug Development 52

The Pharma Data

OCTOBER 25, 2021

First immunotherapy combination to demonstrate superior clinical outcomes over standard of care in a global, randomised trial in this setting. Positive high- position results from the TOPAZ-1 Phase III trial showed Imfinzi (durvalumab), in combination with standard-of- care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival ( Zilches) benefit versus chemotherapy alone as a 1st- line treatment for cases with advanced biliary tract cancer (BTC).

Trials 52

Trials Treatment Hospitals International 52